Compare Noble Corporation plc (NE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Summit Therapeutics Inc — how do they compare? Noble Corporation plc trades at $44.09 (market cap $7.10B), while Summit Therapeutics Inc trades at $15.09 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Noble Corporation plc pays a 4.5% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NE | SMMT | |
|---|---|---|
Market Cap | $7.10B | $12.06B |
Sector | Technology | Health |
52-Week High | $54.37 | $26.98 |
52-Week Low | $26.61 | $12.55 |
Enterprise Value | $8.53B | $11.39B |
Dividend Yield | 4.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $44.21, up 1.52% today, with a mixed technical and fundamental backdrop. The stock exhibits a bullish trend in moving averages but faces resistance near $45-$46. Recent Q2 2026 earnings of $0.01 per share missed expectations, though the company secured $200 million in new contracts and maintains a $6.8 billion backlog. Positive cash flow from operations of $952 million in 2025 supports financial stability, but net income declined year-over-year.
The outlook is cautiously optimistic, with a consensus price target of $46 offering modest upside. Key opportunities include strong contract backlog and operational cash flow, while risks involve earnings volatility, ongoing legal investigations, and competitive pressures in offshore drilling. Analyst sentiment is divided, with 31% buy ratings reflecting balanced optimism and caution.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
